| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biot...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Benitec Biopharma (NASDAQ:BNTC) with a Buy and raises the price...
Citizens analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and raises the price tar...
Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechn...
JMP Securities analyst Silvan Tuerkcan reiterates Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and maintains $20...
-SEC Filing
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $...